225 related articles for article (PubMed ID: 20102938)
1. Safety and in-hospital outcomes of bivalirudin use in dialysis patients undergoing percutaneous coronary intervention.
Delhaye C; Maluenda G; Wakabayashi K; Ben-Dor I; Collins SD; Syed AI; Gonzalez MA; Gaglia MA; Torguson R; Xue Z; Suddath WO; Satler LF; Kent KM; Lindsay J; Pichard AD; Waksman R
Am J Cardiol; 2010 Feb; 105(3):297-301. PubMed ID: 20102938
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of bivalirudin for percutaneous coronary intervention with rotational atherectomy.
Delhaye C; Wakabayashi K; Maluenda G; Ben-Dor I; Torguson R; Xue Z; Suddath WO; Satler LF; Pichard AD; Kent KM; Lindsay J; Waksman R
J Interv Cardiol; 2010 Jun; 23(3):223-9. PubMed ID: 20636842
[TBL] [Abstract][Full Text] [Related]
3. Bleeding risk and outcomes of Bivalirudin versus Glycoprotein IIb/IIIa inhibitors with targeted low-dose unfractionated Heparin in patients having percutaneous coronary intervention for either stable or unstable angina pectoris.
Steinberg DH; Shah P; Kinnaird T; Pinto Slottow TL; Roy PK; Okabe T; Bonello L; de Labriolle A; Smith KA; Torguson R; Xue Z; Suddath WO; Kent KM; Satler LF; Pichard AD; Lindsay J; Waksman R
Am J Cardiol; 2008 Jul; 102(2):160-4. PubMed ID: 18602514
[TBL] [Abstract][Full Text] [Related]
4. Comparison of bivalirudin monotherapy versus unfractionated heparin plus tirofiban in patients with diabetes mellitus undergoing elective percutaneous coronary intervention.
Tavano D; Visconti G; D'Andrea D; Focaccio A; Golia B; Librera M; Caccavale M; Ricciarelli B; Briguori C
Am J Cardiol; 2009 Nov; 104(9):1222-8. PubMed ID: 19840566
[TBL] [Abstract][Full Text] [Related]
5. Comparison of bivalirudin and unfractionated heparin plus protamine in patients with coronary heart disease undergoing percutaneous coronary intervention (from the Antithrombotic Regimens aNd Outcome [ARNO] trial).
Parodi G; Migliorini A; Valenti R; Bellandi B; Signorini U; Moschi G; Buonamici P; Cerisano G; Antoniucci D
Am J Cardiol; 2010 Apr; 105(8):1053-9. PubMed ID: 20381652
[TBL] [Abstract][Full Text] [Related]
6. Comparison of heparin and bivalirudin in patients undergoing percutaneous coronary intervention without use of glycoprotein IIb/IIIa inhibitors.
Abtahian F; Waldo S; Jang IK
Catheter Cardiovasc Interv; 2015 Sep; 86(3):390-6. PubMed ID: 25753749
[TBL] [Abstract][Full Text] [Related]
7. Comparison of safety and efficacy of bivalirudin versus unfractionated heparin in high-risk patients undergoing percutaneous coronary intervention (from the Anti-Thrombotic Strategy for Reduction of Myocardial Damage During Angioplasty-Bivalirudin vs Heparin study).
Patti G; Pasceri V; D'Antonio L; D'Ambrosio A; Macrì M; Dicuonzo G; Colonna G; Montinaro A; Di Sciascio G
Am J Cardiol; 2012 Aug; 110(4):478-84. PubMed ID: 22583760
[TBL] [Abstract][Full Text] [Related]
8. The comparative safety and effectiveness of bivalirudin versus heparin monotherapy in patients on dialysis undergoing percutaneous coronary intervention: Insights from the Blue Cross Blue Shield of Michigan cardiovascular consortium.
Sukul D; Seth M; Schreiber T; Khandelwal A; Cannon LA; LaLonde TA; Gurm HS
Catheter Cardiovasc Interv; 2017 Nov; 90(5):724-732. PubMed ID: 28303632
[TBL] [Abstract][Full Text] [Related]
9. Bleeding after percutaneous coronary intervention with Bivalirudin or unfractionated Heparin and one-year mortality.
Ndrepepa G; Schulz S; Keta D; Mehilli J; Birkmeier A; Massberg S; Laugwitz KL; Neumann FJ; Seyfarth M; Berger PB; Schömig A; Kastrati A
Am J Cardiol; 2010 Jan; 105(2):163-7. PubMed ID: 20102912
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of bivalirudin in patients with diabetes mellitus undergoing percutaneous coronary intervention in current clinical practice.
Kim LK; Wong SC; Minutello RM; Bergman G; Feldman DN
J Invasive Cardiol; 2010 Mar; 22(3):94-100. PubMed ID: 20197573
[TBL] [Abstract][Full Text] [Related]
11. Bivalirudin in percutaneous coronary intervention for chronic total occlusion: A single-center pilot study.
Li C; Xu R; Shen Y; Dai Y; Zhang F; Ma J; Ge L; Qian J; Ge J
Catheter Cardiovasc Interv; 2018 Mar; 91(4):679-685. PubMed ID: 28766879
[TBL] [Abstract][Full Text] [Related]
12. Bivalirudin in PCI: an overview of the REPLACE-2 trial.
Maroo A; Lincoff AM
Semin Thromb Hemost; 2004 Jun; 30(3):329-36. PubMed ID: 15282655
[TBL] [Abstract][Full Text] [Related]
13. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndrome initially treated with fondaparinux: results from an international, multicenter, randomized pilot study (SWITCH III).
Waksman R; Bertrand O; Driesman M; Gruberg L; Rossi J; Mehta S; Swymelar S; Dvir D; Xue Z; Torguson R
J Interv Cardiol; 2013 Apr; 26(2):107-13. PubMed ID: 23240743
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of bivalirudin with and without glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention 1-year results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial.
White HD; Ohman EM; Lincoff AM; Bertrand ME; Colombo A; McLaurin BT; Cox DA; Pocock SJ; Ware JA; Manoukian SV; Lansky AJ; Mehran R; Moses JW; Stone GW
J Am Coll Cardiol; 2008 Sep; 52(10):807-14. PubMed ID: 18755342
[TBL] [Abstract][Full Text] [Related]
15. Comparison of patient outcomes with bivalirudin versus unfractionated heparin in percutaneous coronary intervention.
Watson K; Seybert AL; Saul MI; Lee JS; Kane-Gill SL
Pharmacotherapy; 2007 May; 27(5):647-56. PubMed ID: 17461699
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of a prolonged bivalirudin infusion after urgent and complex percutaneous coronary interventions: a descriptive study.
Cortese B; Micheli A; Picchi A; Bandinelli L; Brizi MG; Severi S; Limbruno U
Coron Artery Dis; 2009 Aug; 20(5):348-53. PubMed ID: 19543084
[TBL] [Abstract][Full Text] [Related]
17. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention in high-bleeding-risk patients with acute coronary syndrome in contemporary practice.
Zhang Y; Zhang Y; Liu Z; Zhang B; Liu G; Chen K
Biomed Pharmacother; 2020 Oct; 130():110758. PubMed ID: 34321166
[TBL] [Abstract][Full Text] [Related]
18. Benefit of bivalirudin versus heparin after transradial and transfemoral percutaneous coronary intervention.
MacHaalany J; Abdelaal E; Bataille Y; Plourde G; Duranleau-Gagnon P; Larose É; Déry JP; Barbeau G; Rinfret S; Rodés-Cabau J; De Larochellière R; Roy L; Costerousse O; Bertrand OF
Am J Cardiol; 2012 Dec; 110(12):1742-8. PubMed ID: 22980964
[TBL] [Abstract][Full Text] [Related]
19. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention.
Kastrati A; Neumann FJ; Mehilli J; Byrne RA; Iijima R; Büttner HJ; Khattab AA; Schulz S; Blankenship JC; Pache J; Minners J; Seyfarth M; Graf I; Skelding KA; Dirschinger J; Richardt G; Berger PB; Schömig A;
N Engl J Med; 2008 Aug; 359(7):688-96. PubMed ID: 18703471
[TBL] [Abstract][Full Text] [Related]
20. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial.
Stone GW; White HD; Ohman EM; Bertrand ME; Lincoff AM; McLaurin BT; Cox DA; Pocock SJ; Ware JH; Feit F; Colombo A; Manoukian SV; Lansky AJ; Mehran R; Moses JW;
Lancet; 2007 Mar; 369(9565):907-19. PubMed ID: 17368152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
